Compare ACNT & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACNT | TTRX |
|---|---|---|
| Founded | 1945 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.2M | 107.2M |
| IPO Year | 1995 | N/A |
| Metric | ACNT | TTRX |
|---|---|---|
| Price | $13.92 | $4.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 69.2K | 19.2K |
| Earning Date | 05-06-2026 | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 106.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.62 | $2.57 |
| 52 Week High | $17.92 | $5.98 |
| Indicator | ACNT | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.96 | 68.92 |
| Support Level | $13.66 | $3.55 |
| Resistance Level | $16.80 | $4.40 |
| Average True Range (ATR) | 0.54 | 0.20 |
| MACD | -0.11 | 0.04 |
| Stochastic Oscillator | 45.73 | 90.41 |
Ascent Industries Co is a specialty chemicals company focused on the development, production, and distribution of tailored, performance-driven chemical solutions. Its customers are spread across energy, household, industrial and institutional (HII), personal care, coatings, adhesives, sealants and elastomers (CASE), agriculture, water treatment, pulp and paper, construction, automotive, and other industrial markets. The company's core product portfolio includes surfactants, defoamers, lubricating agents, flame retardants, and specialty intermediates, offered in both petroleum-based and bio-based formulations. Geographically, it generates maximum revenue from the United States, followed by Mexico, Canada, Honduras, Colombia, the Netherlands, Costa Rica, Japan, and other markets.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.